Skip to main content
Equibles
MRK logo

MRK · Merck & Co., Inc. · Financials

Track MRK — free

Use MRK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MRK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$142.37 -0.42 (-0.29%) At close · Oct 8
S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked
Market Cap
$352.29B
Shares
2.47B
Volume · Oct 8 8.41M Avg daily vol (3M) 9.74M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$65.01B +1.3%
FY2025 Revenue FY2007–FY2025
Net Income
$18.25B +6.6%
FY2025 Net Income FY2007–FY2025
Gross Margin
74.8% -1.5pp
FY2025 Gross Margin FY2007–FY2025
Diluted EPS
$7.28 +8%
FY2025 Diluted EPS FY2007–FY2025
Operating Cash Flow
$16.47B -23.3%
FY2025 Operating Cash Flow FY2007–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics
Annual Quarterly
Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2007
$66.3B – $67.3B $66.57B $65.01B $64.17BG $60.12BG $59.28BG $48.7BG $41.52BG $39.12B $42.29B $40.12B $39.81B — — — — — $45.99B $27.43B $23.85B $24.2B
— $18B $16.38B $15.19B $16.13B $17.41B $13.63B $13.62B $12.02B $13.51B $12.91B $14.03B $14.93B $16.77B $16.95B $16.45B $16.87B $18.4B $9.02B $5.58B $6.14B
— $48.57B $48.63B $48.98B $43.99B $41.87B $35.08B $27.9B $27.11B $28.79B $27.21B $25.78B — — — — — $27.59B $18.41B $18.27B $18.06B
— — 74.8% 76.32% 73.17% 70.63% 72.02% 67.2% 69.29% 68.06% 67.82% 64.75% — — — — — 60% 67.12% 76.59% 74.62%
— $30.45B $15.79B $17.94B $30.53B $13.55B $12.25B $13.4B $9.72B $9.75B $10.34B $10.26B $6.7B $7.18B $7.5B $8.17B $8.47B $11.11B $5.85B $4.81B $4.88B
— $11.14B $10.73B $10.82B $10.5B $10.04B $9.63B $8.96B $9.46B $10.1B $10.07B $10.02B $10.31B $11.61B $11.91B $12.78B $13.73B $13.13B $8.54B $7.38B $7.56B
— — $2.8B $2.4B $2B $2.1B $1.6B $1.8B $1.7B $3.1B $3.2B $3.8B $4.8B $4.2B $4.8B $5B $5.1B $4.7B — — —
— $3.66B — — — — — — $3.65B $4.52B $4.68B $5.47B $6.38B $6.69B $6.99B $6.98B $7.43B $7.38B $2.58B $1.63B $1.99B
— $606M $889M $309M $599M $337M $661M $575M $626M $632M $776M $651M $619M $1.01B $1.71B $664M $1.31B $985M $1.63B $1.03B $327.1M
— $1.74B $1.36B $1.27B $1.15B $962M $806M $831M $893M $772M $754M $693M $672M $732M $801M $714M $695M $715M $460M $251M —
— $235M $343M $415M $365M $157M $36M $59M $274M $343M $385M $328M $289M $266M $264M $232M $145M $83M $210M $631M —
— -$430M -$151M $24M -$466M -$1.5B $1.34B $890M -$129M $402M $500M -$189M -$1.53B $11.61B -$411M -$1.12B -$946M -$1.3B $10.67B $2.32B $75.2M
— $125M — — — — — — — — $42M $86M $205M $257M $404M $642M $610M $587M $2.24B $2.56B $2.98B
— $5.95B $21.07B $19.94B $1.89B $16.44B $13.88B $5.86B $7.17B $8.7B $6.52B $4.66B $5.4B $17.28B $5.55B $8.74B $7.33B $1.65B $15.29B — —
— $2.78B $2.8B $2.8B $1.51B $1.92B $1.52B $1.34B $1.57B $2.51B $4.1B $718M $942M $5.35B $1.03B $2.44B $942M $671M $2.27B $2B $95.3M
— $3.17B $18.25B $17.12B $365M $14.52B $13.05B $7.07B $9.84B $6.22B $2.39B $3.92B $4.44B $11.92B $4.4B $6.17B $6.27B $861M $12.9B $7.81B $3.28B
— — 28.08% 26.68% 0.61% 24.49% 26.79% 17.02% 25.16% 14.71% 5.97% 9.85% — — — — — 1.87% 47.03% 32.74% 13.54%
— -$3M $9M $16M $12M $7M $16M $15M -$66M -$27M $24M $21M $17M $14M $113M $131M $120M $121M $123M $124M $121.4M
— $3.17B $18.25B $17.12B $365M $14.52B $13.05B $7.07B $9.84B — — — — $11.92B $4.4B $6.17B $6.26B $859M $12.85B $7.79B $3.28B
— $4.65B $18.91B $17.33B -$28M $14.18B $14.81B $6.63B $9.2B $5.86B $2.71B $2.84B $4.62B $9.79B $6.89B $4.62B $6.36B — — — —
USD/shares — $1.27 $7.30 $6.76 $0.14 $5.73 $5.16 $2.79 $3.84 $2.23 $0.84 $1.35 $1.51 $3.93 $1.42 $1.94 $1.95 $0.27 $5.41 $3.48 $1.44
USD/shares $2.66 – $2.76* $1.25 $7.28 $6.74 $0.14G $5.71G $5.14G $2.78G $3.81 $2.21 $0.83 $1.35 $1.49 $3.88 $1.40 $1.91 $1.93 $0.27 $5.39 $3.46 $1.42
shares — — 2.5B 2.53B 2.54B 2.53B 2.53B 2.53B 2.57B 2.79B 2.86B 2.9B 2.95B 3.03B 3.11B 3.19B 3.22B 3243.56 2.38B 2.24B —
shares — — 2.51B 2.54B 2.55B 2.54B 2.54B 2.54B 2.58B 2.81B 2.88B 2.92B 2.98B 3.07B 3.14B 3.22B 3.24B 3269.76 2.38B 2.25B —
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $59.84B in buybacks, $104.24B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current debt and lease obligations 2026-06-30 USD 2,825,000,000 10-Q filed 2026-08-07
Noncurrent debt carrying amount 2026-06-30 USD 51,081,000,000 10-Q filed 2026-08-07
8 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

4.300% Notes due 2028

Note · Merck & Co., Inc.

Reference: 4.300% Notes due 2028

Active
Original principal
USD 1,000,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 4.3% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 1,000,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

4.650% Notes due 2031

Note · Merck & Co., Inc.

Reference: 4.650% Notes due 2031

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 4.65% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

4.950% Notes due 2033

Note · Merck & Co., Inc.

Reference: 4.950% Notes due 2033

Active
Original principal
USD 1,000,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 4.95% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 1,000,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

5.200% Notes due 2036

Note · Merck & Co., Inc.

Reference: 5.200% Notes due 2036

Active
Original principal
USD 1,500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 5.2% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 1,500,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

5.750% Notes due 2046

Note · Merck & Co., Inc.

Reference: 5.750% Notes due 2046

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 5.75% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

5.850% Notes due 2056

Note · Merck & Co., Inc.

Reference: 5.850% Notes due 2056

Active
Original principal
USD 1,000,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 5.85% Reported 2026-05-22 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 1,000,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

Floating Rate Notes due 2028

Note · Merck & Co., Inc.

Reference: Floating Rate Notes due 2028

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-05-22 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2026-05-22
    On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Issuer evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.
    Supporting evidence: On May 22, 2026, Merck & Co., Inc. (the “Company”) closed an underwritten public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 4.300% Notes due 2028 (the “2028 Notes”), $500,000,000 aggregate principal amount of 4.650% Notes due 2031 (the “2031 Notes”), $1,000,000,000 aggregate principal amount of 4.950% Notes due 2033 (the “2033 Notes”), $1,500,000,000 aggregate principal amount of 5.200% Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of 5.750% Notes due 2046 (the “2046 Notes”) and $1,000,000,000 aggregate principal amount of 5.850% Notes due 2056 (the “2056 Notes” and, together with the Floating Rate Notes, the 2028 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes and the 2046 Notes, collectively, the “Notes”) under the Company’s Registration Statement on Form S-3ASR (Registration No. 333-278066), originally filed with the Securities and Exchange Commission (the “Commission”) on March 19, 2024, as amended by Post-Effective Amendment No. 1, filed with the Commission on May 14, 2024.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
5.99×
Peer median 6.75×
EV/EBIT
—
P/E (TTM)
114.23×
Peer median 33.32×

Peer medians compare against the 7 similar-size Drug Manufacturers - General companies (of 13 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Pharmaceuticalsegment $58,142,000,000 $57,400,000,000 $53,583,000,000 $52,005,000,000 $42,754,000,000 $36,610,000,000 $34,100,000,000 $37,689,000,000
Animal Health Segment $6,354,000,000 $5,877,000,000 $5,625,000,000 $5,550,000,000 $5,568,000,000 $4,703,000,000 $4,393,000,000 $4,212,000,000
All Other Segments — — — $0 $0 $23,000,000 $175,000,000 $250,000,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $36,362,000,000 $32,151,000,000 $28,343,000,000 $26,811,000,000 $22,159,000,000 $19,517,000,000 $18,334,000,000 $18,228,000,000
Non Us $28,134,000,000 $31,126,000,000 $30,865,000,000 — — — — —
EMEA $14,580,000,000 $14,041,000,000 $13,254,000,000 $14,493,000,000 $13,341,000,000 $11,547,000,000 $10,496,000,000 $12,213,000,000
Latin America $3,410,000,000 $3,459,000,000 $3,086,000,000 $2,582,000,000 $2,206,000,000 $1,890,000,000 $2,015,000,000 $2,415,000,000
Asia Pacific $2,983,000,000 $3,058,000,000 $3,225,000,000 $3,614,000,000 $2,407,000,000 $2,113,000,000 $2,126,000,000 $2,909,000,000
Other Countries $2,878,000,000 $2,559,000,000 $2,104,000,000 $2,568,000,000 $1,221,000,000 $1,027,000,000 $1,275,000,000 $1,015,000,000
Japan $2,711,000,000 $3,280,000,000 $3,164,000,000 $3,629,000,000 $2,726,000,000 $2,602,000,000 $2,609,000,000 $3,212,000,000
China $1,939,000,000 $5,494,000,000 $6,802,000,000 $5,191,000,000 $4,378,000,000 $2,751,000,000 $2,180,000,000 $2,184,000,000
International — $31,126,000,000 $30,865,000,000 $30,744,000,000 $26,163,000,000 $21,819,000,000 $20,333,000,000 $23,923,000,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Keytruda $31,641,000,000 $29,482,000,000 $25,011,000,000 $20,937,000,000 $17,186,000,000 $14,380,000,000 $11,084,000,000 $7,171,000,000
Gardasil Gardasil 9 $5,233,000,000 $8,583,000,000 $8,886,000,000 $6,897,000,000 $5,673,000,000 $3,938,000,000 $3,737,000,000 $3,151,000,000
Livestock $3,896,000,000 $3,462,000,000 $3,337,000,000 $3,300,000,000 $3,295,000,000 $2,939,000,000 $2,784,000,000 $2,630,000,000
Other Pharmaceutical $2,917,000,000 $2,590,000,000 $2,546,000,000 $2,462,000,000 $2,516,000,000 $2,202,000,000 $2,873,000,000 $4,546,000,000
Companion Animals $2,458,000,000 $2,415,000,000 $2,288,000,000 $2,250,000,000 $2,273,000,000 $1,764,000,000 $1,609,000,000 $1,582,000,000
ProQuad MMRII Varivax $2,451,000,000 $2,485,000,000 $2,368,000,000 $2,241,000,000 $2,135,000,000 $1,878,000,000 $2,275,000,000 $1,798,000,000
Bridion $1,841,000,000 $1,764,000,000 $1,842,000,000 $1,685,000,000 $1,532,000,000 $1,198,000,000 $1,131,000,000 $917,000,000
Januvia $1,604,000,000 $1,334,000,000 $2,189,000,000 $2,813,000,000 $3,324,000,000 $3,306,000,000 $3,482,000,000 $3,686,000,000
Alliance Revenue Lynparza $1,450,000,000 $1,311,000,000 $1,199,000,000 $1,116,000,000 $989,000,000 $725,000,000 $444,000,000 $187,000,000
Winrevair $1,443,000,000 $419,000,000 $0 $0 — — — —
Lenvima $1,053,000,000 $1,010,000,000 $960,000,000 $876,000,000 $704,000,000 $580,000,000 $404,000,000 $149,000,000
Prevymis $978,000,000 $785,000,000 $605,000,000 $428,000,000 $370,000,000 $281,000,000 $165,000,000 $72,000,000
Janumet $940,000,000 $935,000,000 $1,177,000,000 $1,700,000,000 $1,964,000,000 $1,971,000,000 $2,041,000,000 $2,228,000,000
Vaxneuvance $825,000,000 $808,000,000 $665,000,000 $170,000,000 $3,000,000 — — —
Capvaxive $759,000,000 $97,000,000 $0 — — — — —
Welireg $716,000,000 $509,000,000 $218,000,000 $123,000,000 $13,000,000 — — —
Rotateq $673,000,000 $711,000,000 $769,000,000 $783,000,000 $807,000,000 $797,000,000 $791,000,000 $728,000,000
Alliance Revenue Reblozyl $525,000,000 $371,000,000 $212,000,000 $166,000,000 $17,000,000 $0 — —
Alliance Revenue Adempas Verquvo $470,000,000 $415,000,000 $367,000,000 $341,000,000 $342,000,000 $281,000,000 $204,000,000 $139,000,000
Lagevrio $380,000,000 $964,000,000 $1,428,000,000 $5,684,000,000 $952,000,000 $0 — —
Isentress Isentress HD $325,000,000 $394,000,000 $483,000,000 $633,000,000 $769,000,000 $857,000,000 $975,000,000 $1,140,000,000
Adempas $312,000,000 $287,000,000 $255,000,000 $238,000,000 $252,000,000 $220,000,000 $215,000,000 $190,000,000
Zerbaxa $312,000,000 $252,000,000 $218,000,000 $169,000,000 -$1,000,000 $130,000,000 $121,000,000 $87,000,000
Delstrigo $306,000,000 $249,000,000 $201,000,000 $151,000,000 — — — —
Dificid $247,000,000 $340,000,000 $302,000,000 $263,000,000 $175,000,000 $110,000,000 — —
Belsomra $186,000,000 $222,000,000 $231,000,000 $258,000,000 $318,000,000 $327,000,000 $306,000,000 $260,000,000
Ohtuvayre $178,000,000 $0 $0 — — — — —
Pifeltro $171,000,000 $163,000,000 $142,000,000 $118,000,000 — — — —
Pneumovax23 $166,000,000 $263,000,000 $412,000,000 $602,000,000 $893,000,000 $1,087,000,000 $926,000,000 $907,000,000
Keytruda Qlex $40,000,000 $0 $0 — — — — —
Remicade $0 $114,000,000 $187,000,000 $207,000,000 $299,000,000 $330,000,000 $411,000,000 $582,000,000
Simponi $0 $543,000,000 $710,000,000 $706,000,000 $825,000,000 $838,000,000 $830,000,000 $893,000,000
Arcoxia — — — — — — $288,000,000 $335,000,000
Atozet — — — — — — $391,000,000 $347,000,000
Cancidas — — — $174,000,000 $212,000,000 $213,000,000 $249,000,000 $326,000,000
Cozaar Hyzaar — — — — — — $442,000,000 $453,000,000
Cubicin — — — — — — $257,000,000 $367,000,000
Emend — — — — — — $388,000,000 $522,000,000
Follistim Aq — — — — — — $241,000,000 $268,000,000
Implanon Nexplanon — — — — — — $787,000,000 $703,000,000
Invanz — — — $189,000,000 $202,000,000 $211,000,000 $263,000,000 $496,000,000
Molnupiravir — — — — $952,000,000 — $0 —
Nasonex — — — — — — $293,000,000 $376,000,000
Noxafil — $177,000,000 $213,000,000 $238,000,000 $259,000,000 $329,000,000 $662,000,000 $742,000,000
Nuvaring — — — — — — $879,000,000 $902,000,000
Primaxin — — $213,000,000 $239,000,000 $259,000,000 $251,000,000 $273,000,000 $265,000,000
Singulair — — — — — — $698,000,000 $708,000,000
Vaqta — — $180,000,000 $173,000,000 $179,000,000 $170,000,000 $238,000,000 $239,000,000
Vytorin — — — — — — $285,000,000 $497,000,000
Zepatier — — — — — — $370,000,000 $455,000,000
Zetia — — — — — — $590,000,000 $857,000,000
Key facts CIK 310158 CUSIP 58933Y105 13F (30d) 172 filings 117 filers Visit website Investor relations